Solving the Growing Incidence of Mental Health Conditions

Through clinical trials of psychedelic inspired medicines and therapies

MindMed Clinical Trials

We are researching & developing a broad range of compounds, with the goal of unlocking new pathways for patients to experience sustained mental healing.

CLINICAL TRIALS

PRE-DISCOVERY

DISCOVERY

PRE-CLINICAL

PHASE 1A

PHASE 2A

PHASE 2B

PHASE 3

MINDMED DEVELOP (Commercial Drug Development Programs)

Anxiety - Project Lucy

Anxiety - Project Lucy

PHASE 2A

18-MC

Opioid Withdrawal

Opioid Withdrawal

PHASE 2A

LSD Microdosing

Adult ADHD

Adult ADHD

PHASE 2A

MINDMED DISCOVER (R&D Collaborations)

University Hospital Basel

LSD Assisted Therapy

Cluster Headaches

Multiple Ongoing or Completed:
 on LSD, MDMA, DMT, Psilocybin

LSD Assisted Therapy

PHASE 2

Cluster Headaches

PHASE 2

Multiple Ongoing or Completed:
 on LSD, MDMA, DMT, Psilocybin

PHASE 1

Our Philosophy

Overcome

We focus on helping patients overcome rather than survive

We believe patients deserve better than to linger in symptom management forever. We help patients make breakthroughs that get them out of the symptom management cycle that’s all too commonplace in mental healthcare.

Community

We’re building a community with high standards of efficacy and compassion

Effective mental healthcare requires a coordinated effort from therapists, drug developers, and patients. We need shared data to drive insights and better treatment, so we’re working to build that community through partnerships and programs. We hold ourselves and our partners to the highest standards of efficacy and compassion so that we can progress the industry — and patient outcomes — faster.

Toolset

Next-Gen R&D

Developing best-in-class mental health care means more than clinical testing. In addition to conducting trials for the compounds we’re bringing to market, we’re also focused on next-gen research & development, comprehensive treatment programs and integrated toolsets that empower therapists to focus on what they do best.

People

We have the right people for the right reasons

Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.

JR Rahn Portrait

JR Rahn

Chief Executive Officer, Board Director, & Co-Founder

Dan Karlin, MD MA Portrait

Dan Karlin, MD MA

Chief Medical Officer

Dr. Miri Halperin Wernli Portrait

Dr. Miri Halperin Wernli

Executive President and Board Director

Robert Barrow Portrait

Robert Barrow

Chief Development Officer

Bradford Cross Portrait

Bradford Cross

Chief Technology Officer

Donald Gehlert, PhD Portrait

Donald Gehlert, PhD

Chief Scientific Officer

Dave Guebert Portrait

Dave Guebert

Chief Financial Officer

Carol Nast Portrait

Carol Nast

Chief Operating Officer

Daniel E. Levy, Ph.D. Portrait

Daniel E. Levy, Ph.D.

Vice President, CMC

Jeanne Bonelle Portrait

Jeanne Bonelle

EVP, Technical Operations

Collin Gage Portrait

Collin Gage

Vice President of Corporate Development

Shahera St. John Portrait

Shahera St. John

VP, Programs

Nico Forte Portrait

Nico Forte

Senior Director, Business Operations and Development

Carole Abel Portrait

Carole Abel

Senior Director Clinical Operations & Program Leader LSD

Madeline Feldman Portrait

Madeline Feldman

Director of Operations & Administration

Julie Tripp Portrait

Julie Tripp

Director of Toxicology

Jon Polaha Portrait

Jon Polaha

Financial Analyst

Stanley D. Glick, PhD, MD Portrait

Stanley D. Glick, PhD, MD

Scientific Advisor

Natalie Wheeler, PhD Portrait

Natalie Wheeler, PhD

Medical Science Liaison with Dova Pharmaceuticals

Matthew W. Johnson, Ph.D Portrait

Matthew W. Johnson, Ph.D

Clinical Advisor

Kenneth Alper, MD Portrait

Kenneth Alper, MD

Clinical Associate Professor of Psychiatry and Neurology at the New York University School of Medicine

Dr. Peter Gasser Portrait

Dr. Peter Gasser

Clinical Advisor

Sarah McCallum, PhD Portrait

Sarah McCallum, PhD

Associate Professor of Neuroscience and Experimental Therapeutics (DNET) at Albany Medical College

John Rotrosen, MD Portrait

John Rotrosen, MD

Professor of Psychiatry with New York University’s Langone’s Department of Psychiatry

Professor Dr. Matthias Liechti, PhD & M.D. Portrait

Professor Dr. Matthias Liechti, PhD & M.D.

Scientific Collaborator & Advisor

Dr. Kim Kuypers Portrait

Dr. Kim Kuypers

Scientific Collaborator & Advisor

Brigid Makes Portrait

Brigid Makes

Board Director, Chair of Audit Commitee, Member of Compensation, Nomination and Governance Committee

Perry Dellelce Portrait

Perry Dellelce

Chairman, Member of Audit and Compensation, Nomination and Governance Committees

Bruce Linton Portrait

Bruce Linton

Board Director, Chair of Compensation, Nomination and Governance Committee, Member of Audit Committee

Stephen L. Hurst, JD Portrait

Stephen L. Hurst, JD

Co-Founder and Board Director

Scott Freeman, MD Portrait

Scott Freeman, MD

Co-Founder & Clinical Advisor

Leonard Latchman Portrait

Leonard Latchman

Co-Founder

Robert G. Wilson III, MBA Portrait

Robert G. Wilson III, MBA

Research Business Director

Jamileh Jemison MD, MS Portrait

Jamileh Jemison MD, MS

Digital Clinical Director

Jakub Klimes, MSc Portrait

Jakub Klimes, MSc

VP, Global Operations

Rachel Chasse, MS Portrait

Rachel Chasse, MS

Sr Clinical Programs Manager

Martin Majernik, MSc., Mgr. Portrait

Martin Majernik, MSc., Mgr.

Director of Digital Product Lifecycle

Matus Hajduk, MSc Portrait

Matus Hajduk, MSc

Sr Clinical Operations Manager

Georgios Lampadariou Portrait

Georgios Lampadariou

Senior Product Manager

Lucia Cesnakova, MSc Portrait

Lucia Cesnakova, MSc

Senior Product Manager

Dana Rajtarova, MA, LL. B. Portrait

Dana Rajtarova, MA, LL. B.

Senior Business Development Manager

Ondrej Skala, MA Portrait

Ondrej Skala, MA

Associate Project Manager

Tomas Stefanicka, MSc Portrait

Tomas Stefanicka, MSc

Infrastructure Lead

Peter Dubec, MSc Portrait

Peter Dubec, MSc

Product Engineering Lead

Alexander Wald, BSc Portrait

Alexander Wald, BSc

iOS Engineer

Adam Kolar, MSc Portrait

Adam Kolar, MSc

Machine Learning Lead

Miguel Amável Pinheiro, PhD Portrait

Miguel Amável Pinheiro, PhD

Machine Learning Lead

Martin Pilch, MSc Portrait

Martin Pilch, MSc

Senior iOS Engineer

Branislav Rariga Portrait

Branislav Rariga

Senior Designer

Ezekiel Powdar Portrait

Ezekiel Powdar

Clinical Research Coordinator

Jay Naik Portrait

Jay Naik

Quality and Regulatory Manager

Michal Lietava Portrait

Michal Lietava

Sr Finance Manager

Enriko Malinak Portrait

Enriko Malinak

Sr Legal Specialist

Alena Vankova, MSc Portrait

Alena Vankova, MSc

Talent & People Ops Specialist

Marketa Svobodova Portrait

Marketa Svobodova

Talent Specialist

Here to Stay

We’re built for operational agility and a long-run business model

This is a rapidly evolving space; we’re committed to building a business that becomes a long-lasting institution in effective mental health treatment — not a flash-in-the-pan startup that’s here today and gone tomorrow.

Patients-first

We’re a new kind of pharma company

We believe that, as a society, we’re at the start of a paradigm shift in mental health. We want to lead the way in doing it right. That means we’re community-focused, honest, and transparent. Together we can improve our collective mental health.

Quotation Marks

This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?”

Kevin O'Leary headshot
Kevin O'Leary Venture Capital Investor

MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”

 headshot

MindMed named one of 36 startups that could change the world

 headshot